Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

Insulin and glucagon exert opposing effects on glucose metabolism and, consequently,
pancreatic islet β-cells and α-cells are considered functional antagonists. The intra-islet …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Obesity is a major public health crisis. Multi-specific peptides have emerged as promising
therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose …

Background Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly
glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week …